Get to know our clinical trials

Clinical trial with belantamab mafodotin in combination with Kd for the treatment of patients with relapsed multiple myeloma refractory to lenalidomide

THE MAIN SPECIFIC OBJECTIVE IS TO INVESTIGATE WHETHER TREATMENT WITH BELANTAMAB MAFODOTIN CARFILZOMIB AND DEXAMETHASONE (KD) IS TOLERABLE AND SAFE AND, SECONDLY, TO DETERMINE THE EFFICACY OF THIS NEW DRUG COMBINATION IN TERMS OF DISEASE-FREE SURVIVAL.

Imagen de la Dra. Paula Rodríguez Otero, especialista de Hematología
Dr. Paula Rodríguez Otero Curriculum
Specialist Hematology and Hemotherapy Department
Navarre headquarters
Madrid headquarters
Cancer Center
Hematologic Cancer Area
Status
In recruitment
headquarters
Pamplona/Madrid

Technical Summary

  • PHASE I/II, OPEN-LABEL, MULTICENTER STUDY OF BELANTAMAB MAFODOTIN IN COMBINATION WITH KD FOR THE TREATMENT OF PATIENTS WITH RELAPSED MULTIPLE MYELOMA REFRACTORY TO LENALIDOMIDE. IMMUNOTHERAPY.
  • Code EudraCT: 2021-002125-15
  • Protocol number: GEM-BELMA
  • Promoter: Fundación Pethema

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

More information about this clinical trial

Information offered by the Spanish Registry of Clinical Studies

  • Summary
  • Information
  • Calendar
  • Headquarters
  • Drugs
Read more about this clinical trial
Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION